Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy

AIDS

Volumn 24, Issue 6, 2010, Pages 885-890

  Murphy, Robert L ^a   Berzins, Baiba ^a   Zala, Carlos ^b   Fichtenbaum, Carl ^c   Dube, Michael P ^d   Guaraldi, Giovanni ^e   Torriani, Francesca ^f   Belsey, Elizabeth ^g   Mitchell, Carol ^h   Stein, James H ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ACLIRES Argentina SRL   (Argentina)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g SigmaClinical ^*  (France)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Atazanavir; Cardiovascular risk; Endothelial function; HIV infection; Hyperlipidemia; Protease inhibitors

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; LIPOPROTEIN; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTERY BLOOD FLOW; ARTICLE; BRACHIAL ARTERY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPIDS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR;

EID: 77949561667     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283352ed5     Document Type: Article

References (22)

1. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D, and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
2. Friis-Moeller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
3. Holmberg SD, Moorman AC, Williamson JM, Weber R, Monforte A, El-Sadr W, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
4. Sabin CA, Worm SW, Weber R, Reiss P, El Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
5. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Weibe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
6. Dubé MP, Gorski JC, Shen C. Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. Cardiovasc Toxicol 2008; 8:15-22.
7. Shanker SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933.
8. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007; 115:1285-1295.
9. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation 2001; 104:257-262.
10. Stein JH, Merwood MA, Bellehumeur JL, Aeschlimann SE, Korcarz CE, Underbakke GL, et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147:E181-E187.
11. Torriani FJ, Komarow L, Parker R, Cotter BR, Currier JS, Dubé MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-näive subjects before and after starting potent antiretroviral therapy. The ACTG Study 5152s. J Am Coll Cardiol 2008; 52:569-576.
12. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive post-menopausal women. J Am Coll Cardiol 2002; 40:505-510.
13. Wood R, Phanuphak P, Cahn P, Pokrovskiy V, Rozenbaum W, Pantaleao G, et al. Long-term efficacy and safety of atazanvir in combination with stavudine and lamivuding in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36:684-692.
14. Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, Ribera E, et al. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defic Syndr 2009; 51:29-36.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor DF, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
16. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Char-bonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial dependent flow-mediated vasodila-tion of the brachial artery: a report of the International Bra-chial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265.
17. Sorensen KE, Celermajer DS, Speigelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, et al. Noninvasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74:247-253.
18. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004; 17:1086-1119.
19. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006; 26:847-870.
20. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005; 352:1611-1613.
21. Flammer AJ, Vo NTT, Ledergerber B, Hermann F, Gämperli A, Huttner A, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart 2009; 95:385-390.
22. Dubé MP, Shen C, Greenwald M, Mather KJ. No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial. Clin Infect Dis 2008; 47:567-574.